Bashir K, Whitaker J N
Department of Neurology, University of Alabama at Birmingham 35233-7340, USA.
Immunol Cell Biol. 1998 Feb;76(1):55-64. doi: 10.1046/j.1440-1711.1998.00714.x.
The underlying pathophysiology of multiple sclerosis is presumed to be autoimmune in nature. Attempts to find an effective treatment for this common disease of the central nervous system have primarily focused on immune-mediated therapies, both immunosuppressive and immunomodulatory. The wide variety of immunological abnormalities detected in multiple sclerosis and its animal model, experimental allergic encephalomyelitis, has prompted the testing of a diverse array of drugs to be used for treatment. Recent successes in the treatment of relapsing-remitting multiple sclerosis with interferon beta and glatiramer acetate have renewed interest in and raised expectations for the effective control of this neurological disorder. Improved methodology in clinical trials, the development of surrogate markers and the availability of novel therapies bode well for more rapid advances.
多发性硬化症的潜在病理生理学被认为本质上是自身免疫性的。为这种中枢神经系统常见疾病寻找有效治疗方法的尝试主要集中在免疫介导的疗法上，包括免疫抑制和免疫调节疗法。在多发性硬化症及其动物模型实验性变应性脑脊髓炎中检测到的各种各样的免疫异常，促使人们测试多种用于治疗的药物。最近使用干扰素β和醋酸格拉替雷治疗复发缓解型多发性硬化症取得的成功，重新激发了人们对有效控制这种神经疾病的兴趣并提高了期望。临床试验方法的改进、替代标志物的开发以及新疗法的出现预示着将取得更快的进展。
